Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Cadrenal Therapeutics, Inc.

CVKD · Nasdaq · CIK 0001937993 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

22 Form 4 transaction lines observed in the same window
22 sales · 0 option, withholding, award, gift or other lines

Last qualifying purchase2023-10-05 · MURPHY JOHN RAYMOND · $1.8K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Pham Quang XChairman, CEO and Interim CFO
▼▼▼▼▼▼▼▼▼▼▼▼▼▼▼▼▼▼▼▼▼▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-10-05 · MURPHY JOHN RAYMOND.

Recent Form 4 activity

0Purchases
27Sales
0Other Form 4 lines
13SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING22 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
105,945
Previous report
118,800
Avg daily volume
98,169
Days to cover
1.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2023-10-05MURPHY JOHN RAYMONDPurchase (P)Common Stock2,669USD 0.69USD 1,842SEC filing ↗
2023-10-04MURPHY JOHN RAYMONDPurchase (P)Common Stock17,331USD 0.70USD 12,132SEC filing ↗
2023-09-05Pham Quang XPurchase (P)Common Stock40,000USD 0.91USD 36,200SEC filing ↗
2023-09-01Pham Quang XPurchase (P)Common Stock70,000USD 0.91USD 63,900SEC filing ↗
2023-03-21MURPHY JOHN RAYMONDPurchase (P)Common Stock10,000USD 1.39USD 13,900SEC filing ↗
2023-03-16MURPHY JOHN RAYMONDPurchase (P)Common Stock20,000USD 1.67USD 33,400SEC filing ↗

Form 4 evidence

27 transaction lines in the latest 365-day window; 62 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-29Pham Quang XSale (S)Common Stock7,400USD 3.03USD 22,422SEC filing ↗
2026-06-26Pham Quang XSale (S)Common Stock9,029USD 3.05USD 27,538SEC filing ↗
2026-06-25Pham Quang XSale (S)Common Stock2,127USD 3.00USD 6,381SEC filing ↗
Show recent Form 4 evidence (27 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-29Pham Quang XSale (S)Common Stock7,400USD 3.03USD 22,422SEC filing ↗
2026-06-26Pham Quang XSale (S)Common Stock9,029USD 3.05USD 27,538SEC filing ↗
2026-06-25Pham Quang XSale (S)Common Stock2,127USD 3.00USD 6,381SEC filing ↗
2026-06-23Pham Quang XSale (S)Common Stock2,277USD 3.20USD 7,286SEC filing ↗
2026-06-22Pham Quang XSale (S)Common Stock9,167USD 3.55USD 32,543SEC filing ↗
2026-06-17Pham Quang XSale (S)Common Stock513USD 3.16USD 1,621SEC filing ↗
2026-06-16Pham Quang XSale (S)Common Stock3,613USD 3.18USD 11,489SEC filing ↗
2026-06-15Pham Quang XSale (S)Common Stock3,666USD 3.58USD 13,124SEC filing ↗
2026-06-12Pham Quang XSale (S)Common Stock12,996USD 3.94USD 51,204SEC filing ↗
2026-06-11Pham Quang XSale (S)Common Stock1,462USD 4.12USD 6,023SEC filing ↗
2026-06-10Pham Quang XSale (S)Common Stock3,500USD 4.21USD 14,735SEC filing ↗
2026-06-09Pham Quang XSale (S)Common Stock12,992USD 4.06USD 52,748SEC filing ↗
2026-06-08Pham Quang XSale (S)Common Stock5,893USD 4.38USD 25,811SEC filing ↗
2026-06-05Pham Quang XSale (S)Common Stock2,064USD 4.42USD 9,123SEC filing ↗
2026-06-04Pham Quang XSale (S)Common Stock3,898USD 4.41USD 17,190SEC filing ↗
2026-06-03Pham Quang XSale (S)Common Stock2,323USD 4.26USD 9,896SEC filing ↗
2026-06-02Pham Quang XSale (S)Common Stock349USD 4.46USD 1,557SEC filing ↗
2026-05-29Pham Quang XSale (S)Common Stock303USD 5.01USD 1,518SEC filing ↗
2026-05-28Pham Quang XSale (S)Common Stock2,989USD 4.93USD 14,736SEC filing ↗
2026-05-22Pham Quang XSale (S)Common Stock1,165USD 5.69USD 6,629SEC filing ↗
2026-05-12Pham Quang XSale (S)Common Stock3,298USD 5.28USD 17,413SEC filing ↗
2026-05-11Pham Quang XSale (S)Common Stock6,476USD 5.76USD 37,302SEC filing ↗
2025-12-29Szot Matthew KSale (S)Common Stock9,933USD 6.97USD 69,233SEC filing ↗
2025-10-27Szot Matthew KSale (S)Common Stock1,800USD 13.99USD 25,182SEC filing ↗
2025-10-27Pham Quang XSale (S)Common Stock1,315USD 13.99USD 18,397SEC filing ↗
2025-10-24Szot Matthew KSale (S)Common Stock1,800USD 13.99USD 25,182SEC filing ↗
2025-10-24Pham Quang XSale (S)Common Stock1,129USD 14.03USD 15,840SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCVKD
CIK0001937993
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history62 transaction lines from 2023-01-24 to 2026-06-29
11 P purchase lines · 45 S sale lines · 6 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.